CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study.

Humans Canada Cohort Studies COVID-19 COVID-19 Vaccines Diterpenes HIV Infections Multicenter Studies as Topic Observational Studies as Topic SARS-CoV-2 Vaccination
COVID-19 HIV & AIDS immunology virology

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
16 12 2021
Historique:
entrez: 17 12 2021
pubmed: 18 12 2021
medline: 31 12 2021
Statut: epublish

Résumé

Most existing vaccines require higher or additional doses or adjuvants to provide similar protection for people living with HIV (PLWH) compared with HIV-uninfected individuals. Additional research is necessary to inform COVID-19 vaccine use in PLWH. This multicentred observational Canadian cohort study will enrol 400 PLWH aged Research ethics boards at all participating institutions have granted ethics approval for this study. Written informed consent will be obtained from all study participants prior to enrolment. The findings will inform the design of future COVID-19 clinical trials, dosing strategies aimed to improve immune responses and guideline development for PLWH. NCT04894448.

Identifiants

DOI: 10.1136/bmjopen-2021-054208 PMID: 34916326 PMC: PMC8678543
pubmed: 34916326
pii: bmjopen-2021-054208
doi: 10.1136/bmjopen-2021-054208
pmc: PMC8678543
doi:

Substances chimiques

COVID-19 Vaccines 0
Diterpenes 0

Banques de données

ClinicalTrials.gov
['NCT04894448']

Types de publication

Clinical Trial Protocol Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e054208

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: The authors declare that they have no competing interests

Références

N Engl J Med. 2010 Mar 4;362(9):812-22
pubmed: 20200385
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
Viruses. 2020 Oct 26;12(11):
pubmed: 33114742
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Lancet. 2010 Jul 31;376(9738):367-87
pubmed: 20650518
J Infect Dis. 1991 Oct;164(4):761-4
pubmed: 1894937
Front Immunol. 2020 Apr 23;11:717
pubmed: 32391017
BMJ. 2009 Jan 26;338:a3172
pubmed: 19171560
Front Immunol. 2020 Dec 15;11:596631
pubmed: 33384690
Eur Radiol. 2020 Jun;30(6):3178-3187
pubmed: 32052172
HIV Med. 2021 May;22(5):372-378
pubmed: 33368966
BMJ Open. 2021 Jan 8;11(1):e041734
pubmed: 33419911
Curr Genomics. 2020 Dec;21(8):564-575
pubmed: 33414678
Clin Infect Dis. 2009 Feb 1;48(3):328-37
pubmed: 19123868
JAMA. 2020 Jan 7;323(1):19-20
pubmed: 31825458
Clin Infect Dis. 2007 Jul 15;45(2):234-40
pubmed: 17578785
Sci Rep. 2018 Jun 29;8(1):9825
pubmed: 29959387
AIDS. 2021 Sep 1;35(11):1872-1874
pubmed: 33993131
Clin Infect Dis. 2004 May 15;38(10):1478-84
pubmed: 15156488
Clin Infect Dis. 2004 Oct 15;39(8):1207-13
pubmed: 15486846
Blood. 2020 Nov 26;136(22):2588-2591
pubmed: 33001206
JAMA. 2021 Apr 15;:
pubmed: 33856406
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
J Int AIDS Soc. 2020 Nov;23(11):e25639
pubmed: 33222424
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Front Physiol. 2021 Jan 12;11:571416
pubmed: 33510644
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
AIDS. 2018 Feb 20;32(4):487-493
pubmed: 29135579
J Infect Dis. 2017 Dec 19;216(12):1525-1533
pubmed: 29253205
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
HIV Med. 2020 Sep;21 Suppl 2:3-16
pubmed: 32881311
J Infect Dis. 2019 Jul 31;220(5):743-751
pubmed: 31045222
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
Clin Infect Dis. 2005 Oct 1;41(7):1045-8
pubmed: 16142673
J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):297-304
pubmed: 33351530
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
AIDS Patient Care STDS. 2014 Aug;28(8):397-410
pubmed: 25029589
J Infect Dis. 2004 Jan 15;189(2):312-21
pubmed: 14722897
Vaccine. 2008 Jul 4;26(29-30):3551-5
pubmed: 18524433
Front Immunol. 2020 Oct 14;11:583019
pubmed: 33178213
Hum Vaccin. 2009 Jul;5(7):441-9
pubmed: 19377279
Clin Infect Dis. 2021 Jun 15;72(12):e1021-e1029
pubmed: 33252620
Vaccine. 2000 Jul 1;18(26):3040-9
pubmed: 10825608
Front Immunol. 2020 Sep 29;11:569611
pubmed: 33133083
Am J Med. 2019 Apr;132(4):437-446
pubmed: 30611828
Clin Infect Dis. 2020 Jan 2;70(2):232-241
pubmed: 30877304
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
BMJ. 2020 Dec 17;371:m4838
pubmed: 33334862
N Engl J Med. 2021 May 20;384(20):1899-1909
pubmed: 33951374
Curr Opin HIV AIDS. 2014 Jul;9(4):379-85
pubmed: 24840058
J Clin Endocrinol Metab. 2007 Jul;92(7):2506-12
pubmed: 17456578
Clin Infect Dis. 2021 Oct 5;73(7):e1964-e1972
pubmed: 32905581
J Clin Immunol. 2021 Aug;41(6):1146-1153
pubmed: 33983545
J Infect Dis. 2011 Jun 15;203(12):1815-23
pubmed: 21606540
J Infect Dis. 2012 Jun;205 Suppl 3:S375-82
pubmed: 22577211
J Int AIDS Soc. 2015 Jun 29;18:20052
pubmed: 26130226
Clin Infect Dis. 2013 Mar;56(5):727-34
pubmed: 23254417
J Exp Med. 1995 Dec 1;182(6):1727-37
pubmed: 7500017
J Infect Dis. 2003 Apr 15;187(8):1327-31
pubmed: 12696015
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Allergy Clin Immunol. 2020 May;145(5):1309-1321
pubmed: 32386655

Auteurs

Cecilia T Costiniuk (CT)

Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada cecilia.costiniuk@mcgill.ca.
ORCID: 0000-0002-4547-714X

Joel Singer (J)

Canadian Institutes of Health Research (CIHR)--Canadian HIV Trials Network and Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, British Columbia, Canada.
School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.

Marc-André Langlois (MA)

Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.

Iva Kulic (I)

Canadian Institutes of Health Research (CIHR)--Canadian HIV Trials Network and Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, British Columbia, Canada.

Judy Needham (J)

Canadian Institutes of Health Research (CIHR)--Canadian HIV Trials Network and Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, British Columbia, Canada.
ORCID: 0000-0002-6327-176X

Ann Burchell (A)

Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Department of Family and Community Medicine, St Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Ontario, Canada.

Mohammad-Ali Jenabian (MA)

Department of Biological Sciences and CERMO-FC Research Centre, Université du Québec à Montréal (UQAM), Montreal, Quebec, Canada.

Sharon Walmsley (S)

Department of Medicine, Division of Infectious Diseases, Toronto General Hospital, Toronto, Ontario, Canada.

Mario Ostrowski (M)

Clinical Sciences Division and Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
Department of Medicine, Division of Infectious Diseases, St. Michael's Hospital, Toronto, Ontario, Canada.

Colin Kovacs (C)

Maple Leaf Medical Clinic, Toronto, Ontario, Canada.

Darrell Tan (D)

Department of Medicine, Division of Infectious Diseases, University of Toronto, Montreal, Ontario, Canada.
MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Ontario, Canada.

Marianne Harris (M)

Brisith Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Mark Hull (M)

Brisith Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.

Zabrina Brumme (Z)

Brisith Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.

Mark Brockman (M)

Brisith Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.

Shari Margolese (S)

Community Advisory Committee, CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada.

Enrico Mandarino (E)

Community Advisory Committee, CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada.

Jonathan B Angel (JB)

Department of Medicine, Division of Infectious Diseases, The Ottawa Hospital, The Ottawa Hospital Research Institute and Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.

Jean-Pierre Routy (JP)

Department of Medicine, Division of Hematology and Chronic Viral Illness Service, McGill University Health Centre, Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
ORCID: 0000-0001-9897-7589

Aslam H Anis (AH)

Canadian Institutes of Health Research (CIHR)--Canadian HIV Trials Network and Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, British Columbia, Canada.
School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.

Curtis Cooper (C)

Department of Medicine, Division of Infectious Diseases, The Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
ORCID: 0000-0002-3368-3499

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › Canada › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études multicentriques comme sujet › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Études observationnelles comme sujet › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › CTN 328: immunogenicity outcomes in people...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › CTN 328: immunogenicity outcomes in people...